We have located links that may give you full text access.
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Bortezomib: a new therapeutic option for POEMS syndrome.
European Journal of Haematology 2010 Februrary 2
OBJECTIVE: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated.
METHODS: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.
RESULTS: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.
CONCLUSION: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
METHODS: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.
RESULTS: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.
CONCLUSION: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app